| A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (NCT07643272) | Hutchmed | 2026-06-30 |
| A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL (NCT07409428) | Hutchmed | 2026-03-20 |
| HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (NCT07396584) | Hutchmed | 2026-03-04 |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors (NCT07228247) | Hutchmed | 2025-12-16 |
| Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets (NCT07348133) | Hutchmed | 2025-12-11 |
| Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans (NCT07331194) | Hutchmed | 2025-10-28 |
| Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations (NCT07025018) | Hutchmed | 2025-07-15 |
| The Study on Effects of CYP3A and P-glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampin of HMPL-453 Tartrate Tablets (NCT07697157) | Hutchmed | 2025-03-01 |
| Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects (NCT07644442) | Hutchmed | 2025-02-26 |
| Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer (NCT06584032) | Hutchmed | 2024-12-12 |
| Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects (NCT06671873) | Hutchmed | 2024-11-26 |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (NCT06361888) | Hutchmed | 2024-05-08 |
| A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia (NCT06387069) | Hutchmed | 2024-04-26 |
| The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) (NCT06291415) | Hutchmed | 2024-04-02 |
| A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors (NCT05886374) | Hutchmed | 2023-07-06 |
| HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study (NCT05930119) | Hutchmed | 2023-03-17 |
| A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma (NCT05713110) | Hutchmed | 2023-02-13 |
| Human Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects (NCT05781906) | Hutchmed | 2023-02-08 |
| HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study (NCT05720767) | Hutchmed | 2022-11-04 |
| Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) (NCT05522231) | Hutchmed | 2022-10-27 |
| HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (NCT05535933) | Hutchmed | 2022-09-30 |
| Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma (NCT05467943) | Hutchmed | 2022-07-29 |
| A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm (NCT05429008) | Hutchmed | 2022-07-15 |
| HMPL-523 Food Effect and Proton Pump Inhibitor Study (NCT05571787) | Hutchmed | 2022-07-13 |
| HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI (NCT05602597) | Hutchmed | 2022-06-01 |
| Fruquintinib Renal Impairment Study (NCT05216354) | Hutchmed | 2022-03-11 |
| Fruquintinib Hepatic Impairment Study (NCT05216367) | Hutchmed | 2022-03-11 |
| Fruquintinib DDI Study With P-gp and BCRP Substrates (NCT05368805) | Hutchmed | 2022-03-02 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691) | Hutchmed | 2022-02-15 |
| HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT05190068) | Hutchmed | 2022-01-04 |
| A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors (NCT05093322) | Hutchmed | 2021-11-30 |
| Phase III Study on HMPL-523 for Treatment of ITP (NCT05029635) | Hutchmed | 2021-10-27 |
| Open-label Study of Surufatinib in Japanese Patients (NCT05077384) | Hutchmed | 2021-09-02 |
| Open-Label Surufatinib in European Patients With NET (NCT04579679) | Hutchmed | 2021-08-13 |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors (NCT04577963) | Hutchmed | 2021-08-09 |
| A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors (NCT04908046) | Hutchmed | 2021-05-27 |
| A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH (NCT04764474) | Hutchmed | 2021-04-12 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors (NCT04579757) | Hutchmed | 2021-03-05 |
| A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations (NCT04762602) | Hutchmed | 2021-02-28 |
| HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma (NCT04353375) | Hutchmed | 2020-09-03 |
| An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma (NCT03779113) | Hutchmed | 2019-09-26 |
| Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas (NCT03786926) | Hutchmed | 2019-08-26 |
| : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors (NCT03903705) | Hutchmed | 2019-04-25 |
| A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients (NCT04005066) | Hutchmed | 2019-04-20 |